CytoDyn (CYDY) EBITDA Margin (2021 - 2022)
CytoDyn (CYDY) recorded EBITDA Margin of -232129.41% in fiscal Q4 2022 (quarter ended May 31, 2022).
Powered by 
Analysis
CytoDyn (CYDY) EBITDA Margin (2021 - 2022) Analysis & Trends
For FY2022 (ended May 31, 2022), CytoDyn reported EBITDA Margin of -48207.67%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 39.16% |
| 10 | CytoDyn | 312.66 Mn | 270.83 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2022 | -230,435.29% |
| Nov 30, 2021 | -10,789.78% |
| Aug 31, 2021 | -49,778.05% |
API Access
CytoDyn EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CYDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();